CSIMarket
 
Oncotelic Therapeutics Inc   (OTLC)
Other Ticker:  
 
 
Price: $0.0371 $0.00 -11.667%
Day's High: $0.042 Week Perf: -11.67 %
Day's Low: $ 0.04 30 Day Perf: -7.25 %
Volume (M): 20 52 Wk High: $ 0.06
Volume (M$): $ 1 52 Wk Avg: $0.04
Open: $0.04 52 Wk Low: $0.01



 Market Capitalization (Millions $) 15
 Shares Outstanding (Millions) 398
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -16
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Oncotelic Therapeutics Inc
Oncotelic Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative therapies for the treatment of cancer. The company's primary goal is to create targeted drugs that can effectively inhibit the growth and spread of cancer cells while minimizing the side effects often associated with traditional chemotherapy. Oncotelic Therapeutics utilizes advanced technologies, including nanomedicine and RNA interference, to design and develop its drug candidates. These novel therapies aim to improve patient outcomes and provide new solutions in the field of oncology.


   Company Address: 29397 Agoura Road Agoura Hills 91301 CA
   Company Phone Number: 635-7000   Stock Exchange / Ticker: OTLC
   OTLC is expected to report next financial results on April 13, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Oncotelic Therapeutics Inc

Oncotelic Therapeutics Inc Shows Remarkable Revenue Growth, Earns $0.07 Million in Q3 2023

Oncotelic Therapeutics Inc, a leading biopharmaceutical company, recently disclosed its revenue for the third quarter of 2023, which amounted to $0.07 million. This represents a significant improvement from the corresponding quarter of the previous year, where the company experienced a net shortfall of $-0.859 million. In terms of bottom-line performance, Oncotelic Therapeutics Inc achieved a profit of $0.041 million in the third quarter of 2023.
One of the highlights of the company's financial results is the improvement in its profit margins. Oncotelic Therapeutics Inc reported a net margin of 58.66% in the third quarter of 2023, indicating that a significant portion of the company's revenue is being retained as profit. Additionally, the operating margin also edged up to 20.68%, demonstrating the company's ability to effectively manage its operating expenses.

Oncotelic Therapeutics Inc

Oncotelic Therapeutics Inc Faces Significant Financial Challenges as Operating Shortfall Soars in Q2 2023



Oncotelic Therapeutics Inc, a company operating in the Major Pharmaceutical Preparations industry, recently published its financial results for the fiscal three months ending June 30, 2023. The results indicate a significant operating shortfall and a net loss, causing concerns among shareholders and raising questions about the company's ability to sustain its growth. This article will provide an overview of the financial results and their implications for Oncotelic Therapeutics Inc.
Financial Results:
In the second quarter of 2023, Oncotelic Therapeutics Inc reported an operating shortfall of $-6.321904 million. This figure represents a considerable decline compared to the operating shortfall of $-0.256315 million recorded in the same quarter of the previous year. Such a substantial increase in the operating shortfall suggests that the company is facing challenges in generating sufficient revenue.






 

Oncotelic Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com